Core Viewpoint - CStone Pharmaceuticals (01093) reported a 25% year-on-year decline in core earnings to 12.2 billion RMB, aligning with the bank's expectations for the year [1] Financial Performance - The company's core earnings for the second quarter decreased by 22% year-on-year, primarily due to weak sales of NBP, impacted by tighter hospital prescription regulations and the procurement effects of Duomeisu and Jinyouli [1] - Management anticipates an improvement in core earnings for the second half of the year, with product sales expected to grow by at least 5% [1] Target Price and Rating - The bank raised its target price for CStone Pharmaceuticals from HKD 10.08 to HKD 12.11, maintaining a "Buy" rating [1] Licensing Agreements - Since the end of last year, the company has secured six external licensing agreements, with management expecting two more large-scale licenses in the second half, each valued at over USD 5 billion [1] - The company has established a broad proprietary technology platform, including nanoparticle formulations, antibody-drug conjugates, siRNA, and antibody-fusion proteins [1] - Management indicated that 40 to 50 assets have potential for external licensing, suggesting sustainable licensing revenue in the medium to long term [1]

Market Overview - The Hong Kong stock market failed to maintain its strong performance from the previous day, with all three major indices experiencing a collective adjustment. The Hang Seng Index fell by 1.18% or 304.99 points, closing at 25,524.92 points, with a total trading volume of HKD 31.78 billion. The Hang Seng China Enterprises Index decreased by 1.07% to 9,148.66 points, while the Hang Seng Tech Index dropped by 0.74% to 5,782.24 points [1] Blue-Chip Stocks Performance - CSPC Pharmaceutical Group (01093) led the decline among blue-chip stocks, falling by 4.33% to HKD 10.38, with a trading volume of HKD 1.797 billion, contributing a loss of 6.04 points to the Hang Seng Index. Bank of America Securities reported a 14.3% year-on-year decline in total revenue for CSPC in Q2, with attributable net profit down 24% to RMB 1.1 billion. The firm revised its revenue forecasts for 2025 to 2027 down by 25%, 2%, and 11% respectively [2] Sector Highlights - Large technology stocks mostly declined, with Alibaba down 2.57% and Tencent down 0.81%. Gold stocks surged, with China Gold International rising over 10%. Apple is expected to initiate a three-year innovation cycle, boosting related stocks like Lens Technology, which rose over 5%. Gaming stocks and some new consumption concepts performed well, with Melco International Development up over 9% [3][5] Federal Reserve Insights - Federal Reserve Chairman Jerome Powell indicated rising downside risks in the U.S. labor market, suggesting a potential policy adjustment could be appropriate. This statement is seen as a strong signal for a possible interest rate cut as early as September. The market reacted positively, particularly for precious metals, with expectations for further increases in gold prices [4] Gaming Sector Performance - The gaming sector continued its upward trend, with Melco International Development rising 9.27% to HKD 5.54. According to JPMorgan, Macau's gaming revenue for the first 24 days of August reached MOP 17.65 billion, with a daily average of MOP 735 million, reflecting a 9% increase from the previous week [6] Pharmaceutical Sector Challenges - The pharmaceutical sector faced pressure, with several stocks declining. Notably, CStone Pharmaceuticals (09966) fell 6.74% to HKD 10.24. U.S. President Trump's announcement to drastically reduce drug prices could create significant challenges for the global pharmaceutical industry, presenting both opportunities and risks for Chinese biotech stocks [6] Notable Stock Movements - Double Ended Co. (06960) debuted with a 31.29% increase, closing at HKD 19.05. The company focuses on energy storage solutions in the data and communication sectors, with a projected market share of 11.1% by 2024 [7] - Kingsoft Holdings (03918) reached a new high, rising 17.94% to HKD 5.72, reporting a 16.76% year-on-year revenue increase to USD 342 million [8] - Angelalign Technology (06699) saw a 10.28% increase to HKD 75.1, with a 33.1% year-on-year revenue growth reported [9] - Meitu Inc. (01357) rose 7.9% to HKD 11.47 after being included in the MSCI China Index, with Morgan Stanley expressing confidence in its long-term growth potential [10] - Xintai Medical (02291) experienced a significant drop of 12.75% to HKD 23.96 following a major shareholder's sale of shares [11]

美银证券发布研报称，石药集团(01093)次季总收入为63亿元人民币，同比下降14.3%，应占净利润同比 下降24%至11亿元人民币。该行将2025至27年收入预测下调25%、2%及11%;因核心药品降价及原料产 品收入占比提升，下调2025年毛利率预测，同时降2025年每股盈利预测42%，但分别升2026及27年每股 盈利预测32%及8%。因此，目标价由6.9港元升至8.1港元，重申跑输大市评级，因主要药物减价。 ...

智通财经APP获悉，美银证券发布研报称，石药集团(01093)次季总收入为63亿元人民币，同比下降 14.3%，应占净利润同比下降24%至11亿元人民币。该行将2025至27年收入预测下调25%、2%及11%;因 核心药品降价及原料产品收入占比提升，下调2025年毛利率预测，同时降2025年每股盈利预测42%，但 分别升2026及27年每股盈利预测32%及8%。因此，目标价由6.9港元升至8.1港元，重申跑输大市评级， 因主要药物减价。 ...

摩根士丹利发布研报称，石药集团(01093)最新的指引，将2025至27年的总收入预测分别下调6.2%、 4.8%及2.6%。根据最新指引和年度至今的趋势，该行下降集团的毛利率和销售开支比率预测，并提高 了研发开支比率预测，将2025年至26年的经常性纯利预测分别下调10%和6%，并上调2027年预测2%， 而2028至30年的纯利预测则因许可收入的贡献而上调。该行将集团目标价由9.6港元升至11港元，续 予"增持"评级。 ...

智通财经APP获悉，摩根士丹利发布研报称，石药集团(01093)最新的指引，将2025至27年的总收入预测 分别下调6.2%、4.8%及2.6%。根据最新指引和年度至今的趋势，该行下降集团的毛利率和销售开支比 率预测，并提高了研发开支比率预测，将2025年至26年的经常性纯利预测分别下调10%和6%，并上调 2027年预测2%，而2028至30年的纯利预测则因许可收入的贡献而上调。该行将集团目标价由9.6港元升 至11港元，续予"增持"评级。 ...

摩根士丹利发表研报指，石药集团最新指引将2025至27年的总收入预测分别下调6.2%、4.8%及2.6%。 根据最新指引和年度至今的趋势，该行下降集团的毛利率和销售开支比率预测，并提高了研发开支比率 预测，将2025年至26年的经常性纯利预测分别下调10%和6%，并上调2027年预测2%，而2028至30年的 纯利预测则因许可收入的贡献而上调。该行将集团目标价由9.6港元上调至11港元，维持"增持"评级。 ...

Core Viewpoint - The report from CMB International raises the target price for CSPC Pharmaceutical Group (01093) to HKD 9.3 while maintaining a "Neutral" rating, reflecting adjustments in revenue forecasts due to sales pressures on core products [1] Financial Performance - The revenue forecasts for 2025-2026 have been lowered to account for ongoing sales pressures on core products, although the increase in high-margin BD revenue and continuous cost reduction efforts are expected to improve the expense ratio [1] - The company announced an interim dividend of HKD 0.14 per share, with an expected full-year dividend of no less than HKD 0.28 per share, compared to HKD 0.26 per share last year [1] Market Outlook - The company’s prescription drug business faced continued pressure in Q2, but there may be opportunities for sequential improvement in the second half of the year [1] - Despite ongoing challenges from centralized procurement and hospital-end medical insurance fees, there is optimism for a recovery in performance in the second half of 2026-2027, driven by the resolution of these pressures and the positive impact of significant BD upfront payments [1]

交银国际发布研报称，上调石药集团(01093)目标价至9.3港元,维持"中性"评级。该行下调2025-2026年收 入预测以反映核心品种销售面临的压力，但高利润率的BD收入占比提升及持续的降本增效努力可望进 一步改善费用率。将DCF估价模型滚动至2026年。 该行表示,该公司第二季度成药业务持续承压，下半年或有环比改善机会。公司宣布中期股息0.14港元/ 股，全年股利预计不低于0.28港元/股(对照去年0.26港元/股)。公司的存量大单品在第二季度持续受到集 采、院端医保费等压力，但看好下半年及2026-2027年业绩复苏的机会，考虑到上述影响即将出清、重 磅BD首付款对业绩的增厚、以及原料药/功能性食品业务的反弹。因此上调目标价，认为当前公司估值 合理，正向催化剂预期与风险已基本反映在股价中。 ...

Group 1 - The core business of the company is the production of finished drugs and raw materials, with a focus on innovative drugs targeting various therapeutic areas such as neurological diseases, oncology, infections, and cardiovascular diseases [1] - As of mid-2025, the company reported total revenue of 13.273 billion and a net profit of 2.548 billion [1] - The company has an international R&D team dedicated to the discovery, research, and development of small molecule targeted drugs, nanomedicines, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and biopharmaceuticals in the immunology field [1] Group 2 - On August 25, Zhuhai International maintained a buy rating for the company, raising the target price to 12.11 HKD [2]